Amryt Pharma Sustainability Profile
Amryt Pharma, a biopharmaceutical company headquartered in Ireland (IE), is dedicated to developing innovative treatments for rare and complex diseases. Founded in 2015, Amryt has rapidly established itself in the industry, focusing on areas such as dermatology and metabolic disorders. The company’s flagship products, including AP101 for epidermolysis bullosa and AP103 for other dermatological conditions, are distinguished by their unique formulations and targeted delivery mechanisms. Amryt Pharma has achieved significant milestones, including successful product launches and strategic partnerships, positioning itself as a leader in the rare disease market. With a commitment to improving patient outcomes, Amryt continues to expand its global reach, making a meaningful impact in the lives of those affected by challenging health conditions.
DitchCarbon Score
How does Amryt Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Amryt Pharma's score of 63 is higher than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Amryt Pharma's reported carbon emissions
In 2022, Amryt Pharma reported total carbon emissions of approximately 104,300 kg CO2e. This figure includes Scope 1 emissions of about 63,800 kg CO2e, primarily from stationary combustion, Scope 2 emissions of around 12,900 kg CO2e from purchased electricity, and Scope 3 emissions of about 27,600 kg CO2e, mainly attributed to business travel. The company has shown a significant reduction in emissions from previous years, with total emissions of approximately 368,480 kg CO2e in 2021 and about 441,380 kg CO2e in 2020. This indicates a downward trend in their carbon footprint, reflecting their commitment to sustainability. Amryt Pharma is a current subsidiary of Chiesi Farmaceutici S.p.A., which influences its climate initiatives and reporting. However, there are currently no specific reduction targets or climate pledges disclosed by Amryt Pharma. The absence of documented reduction initiatives suggests that while the company is actively reducing emissions, it has not yet formalised specific targets or commitments in line with industry standards such as the Science Based Targets initiative (SBTi). Overall, Amryt Pharma's emissions data and reduction efforts highlight a proactive approach to managing their environmental impact, although further commitments could enhance their sustainability profile.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | |
|---|---|
| Scope 1 | 63,800 |
| Scope 2 | 12,900 |
| Scope 3 | 27,600 |
How Carbon Intensive is Amryt Pharma's Industry?
How Carbon Intensive is Amryt Pharma's Location?
Amryt Pharma's Scope 3 Categories Breakdown
Their carbon footprint includes suppliers and value chain emissions, with Scope 3 emissions accounting for 26% of total emissions under the GHG Protocol, with "Business Travel" representing nearly all of their reported Scope 3 footprint.
Top Scope 3 Categories
Amryt Pharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Amryt Pharma has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
